Skip to main content

CORRECTION article

Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1547382

A Corrigendum on "A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review".Sun K and Wang P

Provisionally accepted
Kai Sun Kai Sun Peng Wang Peng Wang *
  • Yidu Central Hospital of Weifang, Weifang, Shandong Province, China

This article is a correction to:

  1. Report: A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient withEGFR exon20in and PIK3CA mutation: A case report and literature review

    1. Read original article

The final, formatted version of the article will be published soon.

    A Corrigendum on “A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review”.Sun K and Wang P (2024). Front. Oncol. 14:1467722. doi: 10.3389/fonc.2024.1467722.In the published article, two minor errors were identified in Table 1 and Table 2.Due to a carelessness during the proof of the article, the mutant of PIK3CA were incorrectly pasted in NTRK1, which was wild type. We sincerely apologize for the errors and assure readers that it does not impact the interpretation of the case report. After reviewing the original data, the corrected tables are provided below.

    Keywords: EGFR-TKI, PIK3CA mutant, furmonertinib, Synchronous cancer, EGFR-TKI acquired resistance

    Received: 18 Dec 2024; Accepted: 31 Dec 2024.

    Copyright: © 2024 Sun and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Peng Wang, Yidu Central Hospital of Weifang, Weifang, Shandong Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.